Korean J Urol Oncol.  2016 Apr;14(1):10-17. 10.0000/kjuo.2016.14.1.10.

Quality of Life in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy

Affiliations
  • 1Department of Urology, Chonnam National University Medical School, Gwangju, Korea. sydad@hanmail.net

Abstract

Androgen deprivation therapy (ADT) has been one of the standard protocol for treating prostate cancer. The role for hormonal treatment initially was restricted to men with metastatic and inoperable, locally advanced disease. Now it has been extended to neoadjuvant or adjuvant therapy for surgery and radiotherapy, for biochemical relapse after surgery or radiation, and even as primary therapy for non-metastatic disease. Although ADT can improve survival, it can also cause significant morbidity and a decrement in quality of life (QOL). In this article, we discuss QOL problem caused by ADT and suggest for mitigating harm of ADT.

Keyword

Prostate Neoplasms; Gonadotropin-releasing hormone; Quality of life

MeSH Terms

Gonadotropin-Releasing Hormone
Humans
Male
Prostate*
Prostatic Neoplasms*
Quality of Life*
Radiotherapy
Recurrence
Gonadotropin-Releasing Hormone
Full Text Links
  • KJUO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error